FDA Approves Daraxonrasib: What This Landmark Pancreatic Cancer Decision Means for Patients

I wrote previously about the striking survival data behind daraxonrasib, the investigational RAS-targeted drug that nearly doubled median survival in advanced pancreatic cancer in its pivotal trial. That drug now has a name patients will see on a pharmacy label: this week, the U.S. Food and Drug Administration formally approved daraxonrasib, under the brand name Rasonque, for patients with KRAS-mutated metastatic pancreatic cancer. The gap between "promising trial data" and "an approved medicine patients can actually receive" is enormous, so it is worth walking through what actually changes today.

The data behind the approval

In the pivotal trial that supported approval — a study of roughly 500 patients with treatment-resistant metastatic pancreatic cancer whose tumors had progressed after standard chemotherapy — patients treated with daraxonrasib had a median overall survival of about 13.2 months, compared to about 6.7 months with chemotherapy alone: nearly a doubling of survival time in a cancer notorious for offering patients very little. Because more than 90% of pancreatic cancers carry a KRAS mutation, the drug's target population is large — it is not a niche therapy limited to a rare genetic subtype, but relevant to the great majority of patients with this disease.

How the drug works, and why it took so long

For roughly 40 years, mutated RAS proteins, including KRAS, were considered "undruggable" — their smooth surface offered no obvious pocket for a drug molecule to bind. Daraxonrasib uses a "molecular glue" mechanism that binds multiple KRAS mutation subtypes at once, rather than targeting just one specific mutation as some earlier RAS-directed drugs did. This broader mechanism is part of why the trial population was large and diverse, and it is also why researchers and oncologists are watching closely to see whether similar molecular-glue approaches can be applied to other RAS-driven cancers, which include a significant share of colorectal and lung cancers as well.

What patients can expect

Reported side effects include skin rash, mouth sores, diarrhea, and other digestive symptoms, generally with fewer severe adverse events than chemotherapy in the trial — an important consideration for patients whose quality of life during treatment matters as much as the treatment's efficacy. Dr. Andrew Coveler, an oncologist quoted in coverage of the approval, offered a fair summary: this is not a cure, but it is a significant improvement over the options that existed before it.

The access question

I would be doing my patients a disservice if I did not mention cost directly: reporting places the price of a one-month supply at approximately $39,800 in the United States. Even with the FDA's expedited approval pathway, and expanded access that was already reaching some eligible patients before formal approval, the price point raises real questions about global and regional access, including here in the Gulf, where reimbursement pathways for newly approved oncology drugs typically lag behind U.S. approval by months to years. I do not have a definitive answer yet on regional availability or pricing, and I will update patients as that becomes clearer.

What I tell my patients

If you or a family member has metastatic pancreatic cancer, this approval is genuinely important news, and it is worth asking your oncologist directly whether KRAS mutation testing has been done on your tumor and whether daraxonrasib, or trial access to it, is a realistic option in your case. It does not replace the importance of early diagnosis, surgical resection when the tumor is still localized, or existing chemotherapy regimens where they remain appropriate — but for patients with KRAS-mutated, treatment-resistant metastatic disease, it represents the most meaningful survival gain this field has seen in years.

Sources: FDA approval of daraxonrasib (Rasonque) for KRAS-mutated metastatic pancreatic cancer, August 2026; RASolute 302 pivotal trial data, Revolution Medicines.